Stay updated with breaking news from John Beigel. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pivotal results on a variety of next generation approaches are expected soon, as a panel of FDA advisers is set to weigh the future of immunization against SARS-CoV-2.
Scientists do not yet know how well the vaccine and the drug used to treat the infection are working. Two new trials will provide answers.
To prevent the disease from becoming endemic, the U.S. needs a vaccine that stops transmission, but no one knows if Jynneos does that.
The approach, which would require a new emergency authorization, would involve injecting one-fifth of the current dose into the skin instead of a full dose into underlying fat.
"The downside is, if you cut it too far or take too many liberties, you reduce the efficacy." Read more at Boston.com.